Saccharomyces boulardii (SB), a subspecies of S. cerevisiae, is a non-pathogenic biotherapeutic probiotic agent that supports the establishment of friendly bacteria in the gastrointestinal tract (GIT). In the GIT, SB increases the production of secretory IgA (sIgA), short chain fatty acids and the activity of the brush border disaccharide digestive enzymes. It also discourages the growth of unfriendly micro-organisms and reduces digestive inflammatory mediators.